+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Scleroderma"

Scleroderma Market Report 2025 - Product Thumbnail Image

Scleroderma Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Systemic Sclerosis (Scleroderma) - Global Clinical Trials Review, 2024 - Product Thumbnail Image

Systemic Sclerosis (Scleroderma) - Global Clinical Trials Review, 2024

  • Clinical Trials
  • April 2024
  • 390 Pages
  • Global
From
Morphea and Related Disorders - Product Thumbnail Image

Morphea and Related Disorders

  • Book
  • March 2024
Dermatology DDX Deck. Edition No. 3 - Product Thumbnail Image

Dermatology DDX Deck. Edition No. 3

  • Book
  • November 2019
Epigenetics and Dermatology - Product Thumbnail Image

Epigenetics and Dermatology

  • Book
  • February 2015
  • 17 Results (Page 1 of 1)
Loading Indicator

Scleroderma is a chronic skin condition that affects the connective tissue of the skin and other organs. It is characterized by hardening and thickening of the skin, as well as joint pain and stiffness. It can also cause damage to the lungs, heart, and kidneys. Treatment for scleroderma includes medications, physical therapy, and lifestyle changes. The scleroderma market within the context of dermatology is a growing one, with a focus on developing treatments that can improve the quality of life for those affected. There is a need for more effective treatments, as well as better diagnosis and management of the condition. Some companies in the scleroderma market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more